Significant delays exist in industry-sponsored pediatric clinical drug trial start-up and enrollment processes
Contemporary Clinical Trials · 2024
DOI: 10.1016/j.cct.2024.107701 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Contemporary Clinical Trials, 2024. Verfasst von Angie Price und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced Clinical Trials for Children, Rockville, MD, United States of America. Hauptthemen laut MEDLINE: Drug Industry, Clinical Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Significant barriers to advancing pediatric drug development continue despite federal incentives to expedite pediatric drug development. There is an urgent need to improve how clinical trials are designed, implemented, and conducted to increase the number of approved therapeutic interventions for children. METHODS: The Pediatric Improvement Collaborative for Clinical Trials & Research was created to measure timelines and address delays in the pediatric clinical trials process. This multi-site collaborative prospectively monitored sixteen time points in industry-sponsored pediatric clinical drug trials, including times to budget approval, contract execution, ancillary protocol review, Institutional Review Board approval, Site Initiation Visit, and first patient consented. RESULTS: Twenty-four sites contributed data on 330 industry-sponsored pediatric drug studies. The average duration to final study budget approval was 121 (range 3-585) days, to final study Institutional Review Board (IRB) approval was 51 (range 1-205) days, to Site Initiation Visit was 204 (range 23-600) days, and to first patient consented was 239 (range 30-534) days. CONCLUSION: Significant study start-up delays were noted in industry-sponsored clinical drug trials among a large group of pediatric sites. Delays and wide variation in all steps of the study process indicate multiple opportunities for improvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Advanced Clinical Trials for Children, Rockville, MD, United States of America.
- Spark Excellence, LLC, St. Paul, MN, United States of America.
- James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States of America.
- Le Bonheur Children's Hospital, Memphis, TN, United States of America.
- University of Minnesota Masonic Children's Hospital, Minneapolis, MN, United States of America.
- Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, United States of America.
Zitieren
APA
Price, A., Simmons, H., Gehring, E., Davis, L., Fischer, G., Klipsch, A. R., Richmond, E., Sullivan, J. E., & Steiner, S. J. (2024). Significant delays exist in industry-sponsored pediatric clinical drug trial start-up and enrollment processes. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2024.107701
Vancouver
Price A, Simmons H, Gehring E, Davis L, Fischer G, Klipsch AR, et al. Significant delays exist in industry-sponsored pediatric clinical drug trial start-up and enrollment processes. Contemporary Clinical Trials. 2024. doi:10.1016/j.cct.2024.107701
BibTeX
@article{Price2024,
author = {Price, Angie and Simmons, Hannah and Gehring, Emily and Davis, Lauren and Fischer, Gwyneth and Klipsch, Ann R and Richmond, Erin and Sullivan, Janice E and Steiner, Steven J},
title = {Significant delays exist in industry-sponsored pediatric clinical drug trial start-up and enrollment processes},
journal = {Contemporary Clinical Trials},
year = {2024},
doi = {10.1016/j.cct.2024.107701}
}
EUVIMED